Identification and validation of ferroptosis-related prognostic risk model and immune landscape in hepatocellular carcinoma

被引:2
作者
Tang, Fei [1 ,2 ,3 ,4 ]
Wang, Ning [1 ,2 ,3 ,4 ,5 ]
机构
[1] Third Cent Hosp Tianjin, Dept Gastroenterol & Hepatol, Tianjin 300170, Peoples R China
[2] Tianjin Key Lab Extracorporeal Life Support Crit D, Tianjin 300170, Peoples R China
[3] Artificial Cell Engn Technol Res Ctr, Tianjin 300170, Peoples R China
[4] Tianjin Inst Hepatobiliary Dis, Tianjin 300170, Peoples R China
[5] Third Cent Hosp Tianjin, Dept Gastroenterol & Hepatol, 83 Jintang Rd, Tianjin 300170, Peoples R China
关键词
Hepatocellular carcinoma; Ferroptosis; Prognosis; Immune infiltration; Immune checkpoints;
D O I
10.1016/j.imbio.2023.152723
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Ferroptosis has been paid much more attention on account of the correlation with tumorigenesis and development. However, the molecular characteristics and immune landscape of ferroptosis regulators in hepatocellular carcinoma (HCC) have not been fully elucidated.Methods: RNA-sequencing data and matched clinical data were collected from The Cancer Genome Atlas (TCGA) database, then underwent gene expression, genetic variations, prognostic risk model, and immune characterization analyses. An independent cohort from Gene Expression Omnibus (GEO) database was utilized to validate ferroptosis-related prognostic risk model.Results: We first identified the differentially expressed ferroptosis regulators between the tumor tissues and normal controls in HCC. Furthermore, the prognostic risk model based on ferroptosis regulators was constructed, of which the high risk group presented poor clinical outcomes compared to the low risk group. Importantly, the ferroptosis-related prognostic risk model consistently presented excellent prediction ability in recognizing the high and low risk patients according to the validation from an independent cohort. Subsequently, immune landscape analysis uncovered that most of ferroptosis regulatory genes were significantly associated with the infiltration of multiple immune cells and the expression of immune checkpoints in HCC. Moreover, the correlations of risk score with immune cells infiltration and immune checkpoints were determined in HCC.Conclusion: Our study developed a prognostic risk model based on ferroptosis regulatory genes, which could accurately predict the patients' prognosis. Immune characteristics analysis revealed that ferroptosis regulatory genes were associated with immune cells infiltration and immune checkpoints in HCC.
引用
收藏
页数:10
相关论文
共 32 条
[1]   Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion [J].
Angeli, Jose Pedro Friedmann ;
Krysko, Dmitri, V ;
Conrad, Marcus .
NATURE REVIEWS CANCER, 2019, 19 (07) :405-414
[2]   Broadening horizons: the role of ferroptosis in cancer [J].
Chen, Xin ;
Kang, Rui ;
Kroemer, Guido ;
Tang, Daolin .
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (05) :280-296
[3]   Molecular therapies for HCC: Looking outside the box [J].
Faivre, Sandrine ;
Rimassa, Lorenza ;
Finn, Richard S. .
JOURNAL OF HEPATOLOGY, 2020, 72 (02) :342-352
[4]   Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies [J].
Feng, Gen-Sheng ;
Hanley, Kaisa L. ;
Liang, Yan ;
Lin, Xiaoxue .
HEPATOLOGY, 2021, 73 :104-114
[5]   The immune contexture in cancer prognosis and treatment [J].
Fridman, Wolf H. ;
Zitvogel, Laurence ;
Sautes-Fridman, Catherine ;
Kroemer, Guido .
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (12) :717-734
[6]   Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal [J].
Gao, Jianjiong ;
Aksoy, Buelent Arman ;
Dogrusoz, Ugur ;
Dresdner, Gideon ;
Gross, Benjamin ;
Sumer, S. Onur ;
Sun, Yichao ;
Jacobsen, Anders ;
Sinha, Rileen ;
Larsson, Erik ;
Cerami, Ethan ;
Sander, Chris ;
Schultz, Nikolaus .
SCIENCE SIGNALING, 2013, 6 (269) :pl1
[7]   Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches [J].
Greten, Tim F. ;
Wang, Xin W. ;
Korangy, Firouzeh .
GUT, 2015, 64 (05) :842-848
[8]   Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition [J].
Hangauer, Matthew J. ;
Viswanathan, Vasanthi S. ;
Ryan, Matthew J. ;
Bole, Dhruv ;
Eaton, John K. ;
Matov, Alexandre ;
Galeas, Jacqueline ;
Dhruv, Harshil D. ;
Berens, Michael E. ;
Schreiber, Stuart L. ;
McCormick, Frank ;
McManus, Michael T. .
NATURE, 2017, 551 (7679) :247-+
[9]   Targeting Ferroptosis to Iron Out Cancer [J].
Hassannia, Behrouz ;
Vandenabeele, Peter ;
Vanden Berghe, Tom .
CANCER CELL, 2019, 35 (06) :830-849
[10]   Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy [J].
Jiang, Hongli ;
Zhang, Ning ;
Tang, Tongzhong ;
Feng, Feng ;
Sun, Haopeng ;
Qu, Wei .
PHARMACOLOGICAL RESEARCH, 2020, 158